The goal of this registry-based observational study is to establish a comprehensive management plan, which focus on medical therapy, cardiac rehabilitation and active post-market surveillance of medical devices, in patients with cardiovascular diseases (CVD). Patients with CVD mainly refers to four groups of patients：1) post-percutaneous coronary intervention (post-PCI) patients; 2) patients with heart failure (HF); 3) patients with cardiometabolic diseases (CMD); 4) patients with structural heart disease (SHD), and the detailed definition of each group can be found in "Eligibility" section. The main questions this study aims to answer are: * the effectiveness of exercise-based cardiac rehabilitation in improving cardiac function, reducing CVD recurrence and mortality, and promoting quality of life for patients with CVD; * the feasibility of registry-based active post-market surveillance of high-risk medical devices used in cardiovascular surgeries, such as PCI, heart valve replacement, and cardiac resynchronization therapy (CRT); * the utilization of multiomics datasets to identify and dissect cardiovascular heterogeneity in both healthy and diseased populations and to guide precision medicine in patients with CVD; * the analysis and evaluation of the prescription patterns and drug response in patients with CVD.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
MACE (PCI group and CMD group)
Timeframe: Assessed at each scheduled follow-up and all fatal events will be tracked from the death registry
Composite Endpoint：cardiovascular death+ HF-related rehospitalization.
Timeframe: Assessed at each schedule follow-up and all fatal events will be tracked from the death registry
Composite Endpoint：cardiovascular death+ rehospitalization.
Timeframe: Assessed at each scheduled follow-up and all fatal events will be tracked from the death registry